Dr. Noy on the Rationale to Evaluate Devimistat in Burkitt Lymphoma

Ariela Noy, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the rationale to evaluate devimistat (CPI-613) in patients with either Burkitt lymphoma/leukemia or high-grade B-cell lymphoma.

Read the full article here

Related Articles